Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-FAPI Theranostic Pair in Advanced Cancer
NCT04849247Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DOTA-FAPI in cancer (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: 68Ga-DOTA-FAPI PET/CT imaging at 1 hour and 177Lu-DOTA-FAPI dose escalation therapy at 60 days. Status: unknown.
02
Drugs
177Lu-DOTA-FAPI
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04849247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849247.